{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:26:07Z","timestamp":1787199967050,"version":"build-2736575974"},"reference-count":35,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Resmetirom is the first thyroid hormone receptor-beta agonist approved in the United States for adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-advanced fibrosis. Dyslipidemia and cardiovascular risk are common in MASH, making statin co-use clinically relevant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aims to characterize early post-marketing adverse event reporting for resmetirom in the FDA Adverse Event Reporting System (FAERS) and explore resmetirom\u2013statin co-reporting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cleaned and deduplicated FAERS reports from 2024 Q1 to 2026 Q1 were analyzed. Positive preferred-term (PT) signals required at least three reports and concordant positivity for the reporting odds ratio, proportional reporting ratio, and Bayesian information component. Reporter-type sensitivity analysis was restricted to healthcare professional (HCP) reports. Exploratory resmetirom\u2013statin analyses used a suspect-anchored definition and prespecified hepatic, gallbladder-related, and muscle-related outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 3,155,054 unique FAERS cases, 1,407 were included in the resmetirom single-drug analysis and 267 met the primary resmetirom\u2013statin co-reporting definition. Reports were concentrated in gastrointestinal, hepatobiliary, investigation, and skin-related system organ classes. The leading positive PTs were diarrhea, nausea, pruritus, alanine aminotransferase increased, and aspartate aminotransferase increased. The findings were compatible with the FDA label and remained similar in the reporter-type sensitivity analysis. Unlabeled terms among the top 20 signals included weight decreased and abdominal discomfort, which require cautious interpretation. Exploratory DDI analysis did not identify a consistent interaction-specific signal for the prespecified hepatic, gallbladder-related, or muscle-related outcomes. Rhabdomyolysis\/myopathy was based on five co-reports; the odds ratio was elevated, whereas Omega025 was negative.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Early FAERS data indicate a resmetirom reporting spectrum mainly concordant with the FDA label. Unlabeled non-specific PTs, including weight decreased and abdominal discomfort, require cautious interpretation. Resmetirom-statin co-reporting did not show a stable interaction signal.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1895524","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:16:12Z","timestamp":1787199372000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Early post-marketing safety profile of resmetirom in FAERS: an exploratory assessment of statin co-reporting"],"prefix":"10.3389","volume":"17","author":[{"given":"Yongjian","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Huizhou Central People\u2019s Hospital","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaru","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Affiliated Hospital of Guangdong Medical University","place":["Zhanjiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third Affiliated Hospital of Sun Yat-sen University","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yige","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The First Affiliated Hospital of Wenzhou Medical University","place":["Wenzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzhen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Huizhou Central People\u2019s Hospital","place":["Huizhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyu","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Shantou Central Hospital","place":["Shantou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","volume-title":"data.table: Extension of \u2018data.frame\u2019","author":"Barrett","year":"2026"},{"key":"B2","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"Bate","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"key":"B5","doi-asserted-by":"publisher","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B8","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40264-025-01628-4","article-title":"Causal inference tools for pharmacovigilance: using causal graphs to identify and address biases in disproportionality analysis","volume":"49","author":"Fusaroli","year":"2026","journal-title":"Drug Saf."},{"key":"B9","volume-title":"Flextable: Functions for Tabular Reporting","author":"Gohel","year":"2026"},{"key":"B10","volume-title":"Officer: Manipulation of Microsoft Word and Powerpoint Documents","author":"Gohel","year":"2026"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1038\/clpt.2012.50","article-title":"Novel data-mining methodologies for adverse drug event discovery and analysis","volume":"91","author":"Harpaz","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e5768","DOI":"10.1002\/pds.5768","article-title":"Adverse drug reaction signal detection methods in spontaneous reporting system: a systematic review","volume":"33","author":"Jiao","year":"2024","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"goaf097","DOI":"10.1093\/gastro\/goaf097","article-title":"An analysis of safety data from the first year of resmetirom","volume":"13","author":"Kudaravalli","year":"2025","journal-title":"Gastroenterol. Rep."},{"key":"B17","unstructured":"Introductory guide for standardised MedDRA queries (SMQs)\n          \n          \n          2025"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American heart association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1002\/sim.3247","article-title":"A statistical methodology for drug\u2013drug interaction surveillance","volume":"27","author":"Nor\u00e9n","year":"2008","journal-title":"Statistics Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1111\/bcp.14943","article-title":"Statin liver safety in non\u2010alcoholic fatty liver disease: a systematic review and metanalysis","volume":"88","author":"Pastori","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B21","volume-title":"R: A Language and Environment for Statistical Computing","year":"2026"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e0670","DOI":"10.1097\/HC9.0000000000000670","article-title":"Early experience with resmetirom to treat metabolic dysfunction\u2013associated steatohepatitis with fibrosis in a real-world setting","volume":"9","author":"Ravela","year":"2025","journal-title":"Hepatol. Commun."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"","journal-title":"Hepatology"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"","journal-title":"Hepatology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf."},{"key":"B27","volume-title":"Openxlsx: Read, Write and Edit Xlsx Files","author":"Schauberger","year":"2025"},{"key":"B28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","article-title":"Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis","volume":"65","author":"Targher","year":"2016","journal-title":"J. Hepatol."},{"key":"B29","volume-title":"Rezdiffra (Resmetirom) Prescribing Information","year":"2024"},{"key":"B30","unstructured":"FAERS quarterly data extract files\n          \n          \n          2026"},{"key":"B31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1002\/pds.3226","article-title":"Using time to onset for detecting safety signals in spontaneous reports of adverse events following immunization: a proof of concept study","volume":"21","author":"Van Holle","year":"2012","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B33","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"Wickham","year":"2016"},{"key":"B34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1445324","DOI":"10.3389\/fphar.2024.1445324","article-title":"Rhabdomyolysis associated with concomitant use of colchicine and statins in the real world: identifying the likelihood of drug\u2013drug interactions through the FDA adverse event reporting system","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1895524\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:16:15Z","timestamp":1787199375000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1895524\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":35,"alternative-id":["10.3389\/fphar.2026.1895524"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1895524","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1895524"}}